The Pattern

Four major alt AM earnings transcripts processed in 72 hours (BX, ARES, STEP, CG). Every single one shows the same thing:

  • Record recurring fee growth — ARES AUM +29%, BX AUM +13%, STEP FEAUM +21%, CG FRE +12%
  • Performance fee timing lumpiness — SPRING crystallization (STEP), incentive fee normalization (BX), Q4 DE beat then guide down (ARES), net accrued carry +9% sequentially (CG)
  • Aggressive 2026 guidance — Every management team guiding acceleration while stocks crater
  • Stocks getting obliterated — 1-month: ARES -31%, KKR -21%, OWL -20%, BX -16%, CG -15%, STEP -10%

Today (Feb 6): Entire group bounced +2% to +8% on 1.8-2.7× volume. RSI readings at capitulation levels: KKR 9.7, OWL 10.5, BX 12.1, ARES 12.6, STEP 13.2, CG 16.0.

Market is pricing "alt AM peak." Management is unanimously saying "we're accelerating."

Why CG Matters in the Basket

Cheapest valuation: 10.8× forward P/E (vs BX 18×, ARES 16×, KKR 21×) on a platform growing FRE 12%+ organically.

Embedded value floor: $23/share pretax embedded value ($2B cash + $3B investments + $3B net accrued carry) = 39% of $58.71 stock price. Net accrued carry grew +9% sequentially in Q4 alone.

Named catalyst in 20 days: Feb 26 shareholder update. CEO Harvey Schwartz deferred every forward-looking question on the Q4 call to this event, promising "multi-year financial targets" and "strategic direction." Given CG just beat its $40B inflow target by 35% ($54B delivered), new targets should meaningfully reset expectations.

What just happened operationally (Q4 2025):

  • Record FRE $1.24B (+12% YoY), margins 47%
  • Record inflows $54B (vs $40B target, +35%)
  • Record AUM $477B
  • Record transaction revenue $225M (+40% YoY)
  • Returned record $1.2B to shareholders

The three platform bets Schwartz is making:

  1. Private credit buildout — Hired Goldman's Alex Chi for direct lending, Mike Mayer for origination. $30B originations in 2025. Most active US CLO manager (39 priced). Credit FRE $402M (+21% YoY). Closing gap with ARES/OWL.

  2. Wealth channel scale — Zero to three flagship products in 3 years. Evergreen AUM doubled YoY. Hired head of retirement (new role). Wealth org headcount +50%. Retirement = "long-term growth engine." This is early innings in the largest alt TAM.

  3. AlpInvest secondary/co-invest platform — FRE +60% YoY per worker notes. Differentiated capability vs peers.

The Risk No One Hides

Beta: 2.04

This is a leveraged bet on macro. If tariff/recession fears escalate, CG falls harder than most. The Feb 26 catalyst won't save you if the macro selloff deepens.

The Sector Thesis

Every transcript shows management investing into the selloff:

  • BX: 5 PE funds targeting >$50B aggregate, all fee-earning by year-end 2026
  • ARES: Record $113B fundraising in 2025, guiding equal-or-better 2026
  • CG: Beat inflow targets by 35%, Schwartz accelerating credit/wealth buildout
  • STEP: $32.7B undeployed fee-earning capital = 24% of current FEAUM

The selloff is pricing "PE cycle peaked" while every data point says "secular shift to privates accelerating."

What to Watch

Near-term catalyst stack:

  • Feb 26: CG shareholder update (multi-year targets)
  • Q1 2026 earnings (March): Does recurring fee momentum continue across group?
  • Macro: Tariff escalation vs resolution

Position construction:

  • CG: Cheapest on forward earnings, named Feb 26 catalyst, embedded value floor
  • ARES: Highest growth (AUM +29%), but most beaten down (-31%)
  • BX: Largest scale ($1.275T AUM), most diversified, but also most expensive (18× fwd P/E)

Basket approach makes sense — diversifies idiosyncratic risk (STEP's SPW put overhang, BX's real estate drag, CG's beta), concentrates on sector thesis (privates secular shift + oversold technicals + aggressive management guidance).

Sizing Considerations

High beta across the group (CG 2.04, BX 1.76, APO 1.56). This is a macro-sensitive trade with leverage. If you're wrong on "the selloff is overdone," these fall harder than the market.

The setup: Fundamentals accelerating, stocks capitulating, named catalyst in 20 days (CG). Today's bounce (+2-8% on heavy volume) suggests selling exhaustion may be starting.

Not urgent. But the probability-weighted payoff is getting interesting.